


## Claims:

1. Use of compounds of the following formula (I):



wherein X represents OH, (C<sub>1-5</sub>) alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, N(C<sub>1-5</sub> alkyl)<sub>2</sub>;

R<sub>1</sub> is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C<sub>1-5</sub>) alkoxy groups, (C<sub>1-5</sub>) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile;

R<sub>2</sub> is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro;

Y<sub>1</sub> and Y<sub>2</sub> independently from each other represent H or (C<sub>1-5</sub>) alkyl;

R<sub>3</sub> and R<sub>4</sub> independently from each other represent H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>) alkoxy; and

R<sub>5</sub> represents H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy;

or a pharmaceutically acceptable salt thereof;

for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.

2. Use according to claim 1, wherein X represents (C<sub>1-5</sub>) alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub> alkyl)<sub>2</sub>.
3. Use according to claim 1 or 2, wherein R<sub>3</sub> and R<sub>4</sub> independently from each other represent H, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>) alkoxy.
4. Use according to any of the previous claims, wherein R<sub>5</sub> represents H, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy.
5. Use according to any of the previous claims, wherein R<sub>1</sub> is a residue which is derived from one of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted with a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom, or which is derived from Ile.
6. Use according to claim 5, wherein R<sub>1</sub> is a residue which is derived from Phe, which may optionally be substituted with a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom.
7. Use according to any of the previous claims, wherein R<sub>2</sub> is a residue which is derived from the amino acid Gly or Ile.
8. Use according to any of the previous claims, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.